SCHEMBL4628474

SCHEMBL4628474

Cc1ccc(C(=O)N=C(N)N2CCCc3ccccc32)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 1/20 0.86
SMN1; SMN2 Q16637 2/20 0.55
HPGD P15428 2/20 0.55
KMT2A Q03164 2/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
NOTUM Q6P988 1/20 0.53
ALDH1A1 P00352 2/20 0.52
MEN1 O00255 1/20 0.52
LMNA P02545 2/20 0.51
GAA P10253 2/20 0.51
PDE4B Q07343 2/20 0.50
PDE4D Q08499 2/20 0.50
PDE4A P27815 1/20 0.50
PDE4C Q08493 1/20 0.50
TSHR P16473 1/20 0.50
POLB P06746 1/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4629262 0.93 SCN2A (1.00) SCN2ASMN1; SMN2HPGDKMT2ANPC1
SCHEMBL4627586 0.88 SCN2A (0.67) SCN2ASMN1; SMN2HPGDKMT2ANOTUM
SCHEMBL4627492 0.82 SCN2A (0.60) SCN2ASMN1; SMN2HPGDKMT2ANOTUM
SCHEMBL4629438 0.81 SCN2A (0.58) SCN2ANOTUMALDH1A1NPSR1
SCHEMBL3456488 0.80 HPGD (0.83) SMN1; SMN2HPGDKMT2ANPC1RAB9A
SCHEMBL4628490 0.80 POLB (0.69) SCN2ASMN1; SMN2KMT2ANOTUMALDH1A1
SCHEMBL4628733 0.80 SCN2A (0.77) SCN2ASMN1; SMN2HPGDKMT2ANPC1
SCHEMBL4628693 0.77 ALDH1A1 (0.58) SCN2ASMN1; SMN2HPGDKMT2ANPC1
SCHEMBL4629002 0.77 TSHR (0.67) SCN2ASMN1; SMN2HPGDKMT2ANPC1
SCHEMBL4628750 0.75 SCN2A (0.69) SCN2ASMN1; SMN2HPGDKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SCN2A 1613/4885SMN1; SMN2 53/4885HPGD 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.